Evidence map›Paper›PMID 31174846›Full record

Trial reportBiological psychiatry2019

Cholinergic Modulation of Exposure Disrupts Hippocampal Processes and Augments Extinction: Proof-of-Concept Study With Social Anxiety Disorder.

Michelle G Craske, Michael Fanselow, Michael Treanor, Alexander Bystritksy

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Biological psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Enhancing Fear Extinction: Pharmacological Approaches.Current topics in behavioral neurosciences · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Michelle G CraskeStaglin Center for Brain and Behavioral Health, Department of Psychology, Los Angeles, California; Department of Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, California. Electronic address: mcraske@mednet.ucla.edu.
Michael FanselowStaglin Center for Brain and Behavioral Health, Department of Psychology, Los Angeles, California; Department of Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, California.
Michael TreanorStaglin Center for Brain and Behavioral Health, Department of Psychology, Los Angeles, California; Department of Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, California.
Alexander BystritksyDepartment of Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, California.
University of California, Los Angeles · US

Funding

Cholinergic Decontextualization of Exposure Therapy for AnxietyR34MH101359 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CRASKE, MICHELLE G, FANSELOW, MICHAEL S · 2013 to 2015
$693k
NIMH NIH HHS R34 MH101359
6 · The paper itself

Abstract

backgroundIn rodents, context specificity of Pavlovian extinction is attenuated by manipulations that impair hippocampal function, including systemic administration of scopolamine, a muscarinic-cholinergic receptor antagonist. Context renewal translates into return of fear following exposure therapy to feared situations. We evaluated the effectiveness of scopolamine for attenuating context renewal of phobic fear in humans.

methodsA total of 60 participants (35 female, 22 male, 1 transgender, 2 undeclared) with social anxiety disorder and fear of public speaking were randomized to placebo, 0.5 mg scopolamine, or 0.6 mg scopolamine. They completed seven exposure sessions in an exposure context and subsequently tested in the exposure context (extinction retest) versus a different context (context renewal test), which were counterbalanced. Testing 1 month later occurred in the exposure context (long-term extinction retest). Fear measures included skin conductance and self-reported distress during speeches. Hippocampus-dependent cognitive tasks were completed as well.

resultsScopolamine augmented extinction across exposure sessions on skin conductance response and skin conductance level. Lower skin conductance response at context renewal in scopolamine groups relative to the placebo group was constrained to simple effects and complicated by unexpected outcomes within placebo and on self-reported fear. Scopolamine led to lower skin conductance response at long-term extinction retest. Scopolamine impaired performance on a cognitive task of hippocampal function.

conclusionsNoninvasive and well-tolerated scopolamine impaired hippocampal processes and augmented extinction during exposure. Drug-free effects persisted 1 month later. Findings at context renewal were limited and suggestive only. Further investigation is warranted with varying scopolamine dosages.

Indexed as

Extinction, PsychologicalImplosive TherapyAdolescentAdultCholinergic AntagonistsConditioning, ClassicalFearFemaleGalvanic Skin ResponseHippocampusHumansMaleMental RecallPhobia, SocialProof of Concept StudyScopolamineCholinergic AntagonistsScopolamineContext renewalExtinctionFearHippocampusPublic speakingScopolamine

Identifiers

PMID31174846
PMCPMC6788956
OpenAlexW2939767549

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.